Skip to main content
    A

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $21.23
    -0.15 (-0.70%)

    Market Cap: $7.45B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) trades at 21.4x trailing earnings and 2.2x sales. Its P/E of 21.4x is above its 5-year median of 9.8x. Its forward P/E is 18.3x. The median P/E across 11 similar companies is 18.4x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 16.9% higher over the next year. Its free cash flow yield is 0.5%.

    MultipleValue
    P/E (trailing)21.4x
    Forward P/E18.3x
    Price to sales2.2x
    Price to book13.4x
    EV/EBITDA15.3x
    Price to FCF185.5x
    EV/FCF264.1x
    PEG2.0
    FCF yield0.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 98.1% above 10.8x and its P/S is 450.0% above 0.4x.

    MultipleCurrent5-year median10-year median
    P/E21.4x9.8x10.8x
    P/S2.2x0.5x0.4x
    Medians of month-end values through Oct 2026: 59 to 60 months (5-year) and 101 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 2.9x in 2022 to 26.4x in 2017.

    Year endPriceP/EP/SP/B
    2025$12.6015.0x1.3xN/A
    2024$7.9213.7x0.9xN/A
    2023$6.079.5x0.4x74.8x
    2022$1.992.9x0.1x1.0x
    2021$4.795.7x0.3x2.0x
    2020$4.577.3x0.3x2.2x
    2019$4.8213.8x0.4x2.9x
    2018$13.5313.7xN/A1.9x
    2017$16.6526.4x1.9xN/A
    2016$13.2511.3xN/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About AMRX

    What is AMRX's forward P/E ratio?

    Amneal Pharmaceuticals, Inc. Class A Common Stock has a forward P/E ratio of 18.3x.

    Is AMRX stock overvalued?

    GNG's valuation label for AMRX is Overvalued. Its P/E of 21.4x compares with a median of 18.4x across 11 similar companies.

    What is AMRX's price to sales ratio?

    Amneal Pharmaceuticals, Inc. Class A Common Stock has a price to sales ratio of 2.2x.

    What is Amneal Pharmaceuticals, Inc. Class A Common Stock's average P/E ratio over 5 years?

    Amneal Pharmaceuticals, Inc. Class A Common Stock's median P/E over the last 5 years is 9.8x, from 60 month-end values through Oct 2026.

    What is AMRX's PEG ratio?

    Amneal Pharmaceuticals, Inc. Class A Common Stock has a PEG ratio of 2.0.